Purple Biotech

Purple Biotech is a clinical-stage company developing therapies to overcome tumor immune evasion and drug resistance.

A histology stain of pancreatic ductal adenocarcinoma
Biotech

ASCO: Early Purple Biotech data shows gains in pancreatic cancer

Purple’s anti-CEACAM1 antibody, dubbed CM24, was offered to previously treated patients alongside Bristol Myers Squibb’s Opdivo.
Conor Hale Jun 1, 2024 8:00am
paint palette artist paint color brush art

Purple snags Immunorizon's tri-specific antibodies in small M&A

Feb 2, 2023 10:20am